The adhesion of thrombin-stimulated human blood platelets to either the endothelial surface of intact bovine aorta or cultured bovine aortic endothelial cells was studied to determine the role of endothelium-derived relaxing factor in the regulation of platelet adhesion. Endothelial cells and platelets were pretreated with indomethacin to prevent the formation of prostaglandins. The adhesion of thrombinstimulated platelets to endothelial cells was reduced by superoxide dismutase and bradykinin. The inhibitory effect of both drugs was abolished by hemoglobin and was absent in strips of bovine aorta where the endothelial cells had been removed by scraping. It is suggested that the effects of bradykinin are mediated by the release of endothelium-derived relaxing factor, which is protected from destruction by superoxide dismutase, and that endothelium-derived relaxing factor contributes to the nonadhesive properties of the vascular endothelium.
Unstimulated or stimulated blood platelets do not easily adhere either to the intact endothelium (1) or to the surface of intact confluent monolayers of cultured endothelial cells (2) (3) (4) . This nonthrombogenicity appears to be an intrinsic property of the endothelial cell (EC) plasma membrane. In addition to providing a physical barrier between the blood and thrombogenic subendothelial structures, ECs possess both anticoagulant and antiplatelet properties. The anticoagulant properties are expressed in (i) the synthesis and release of a heparin sulphate that promotes the ability of plasma antithrombin III to inactivate thrombin rapidly (5, 6) , (ii) the production of thrombomodulin (7) , and (iii) the synthesis of plasminogen activator (8) . The antiplatelet properties of the EC surface have been variously attributed to (i) a netnegative charge on the endothelial surface (9) , (ii) the presence of an ectoplasmic ATPase that metabolizes aggregatory nucleotides released from aggregating platelets (10) , (iii) the synthesis and release of the antiaggregatory prostanoid prostacyclin (11) , and (iv) the intracellular concentration of 13-hydroxyoctadecadienoic acid, a lipoxygenase product of linoleic acid (12) . The relative contribution of these factors to the nonthrombogenic nature of the EC plasma membrane presently is unknown.
Thromboresistance appears to be unrelated to prostacyclin release, since inhibition of prostacyclin production in cultured ECs does not increase the adhesion of either unstimulated or stimulated platelets (1, 3) , although concentrations of prostacyclin higher than those normally released at the EC surface are highly effective in preventing platelet adhesion (1, 3, 4, 13) . In addition to releasing prostacyclin, ECs respond to mechanical stimulation and to various neurohumoral mediators by releasing vasodilator or vasoconstrictor substances that may contribute to the control of local blood flow (14) . One of the most powerful of these substances is endothelium-derived relaxing factor (EDRF) that is responsible for the endothelium-dependent relaxations produced by a wide variety of vasodilators (15) . In addition to its relaxant effects on vascular smooth muscle EDRF influences platelet function. It is an inhibitor of platelet aggregation (16) (17) (18) , and several substances released from platelets, such as ATP or serotonin, can stimulate ECs to release EDRF (19) . Such a mechanism could provide a negative feedback in which substances released from aggregating platelets act on the EC to release EDRF; EDRF in turn acts to inhibit further platelet aggregation and promote the disaggregation of formed clumps. Furthermore, EDRF-mediated vasorelaxation would permit the increased blood flow to flush away the developing aggregates, further protecting the integrity of essential vascular beds. However, EDRF has a very short half-life of 6-30 sec (20) , is inhibited by haptoglobulin-hemoglobin complex in plasma (21) , and loses its antiaggregatory potency within 4 min of addition to washed platelet suspensions (18) . It is unlikely, therefore, that sufficient EDRF can be present in whole blood to influence platelet aggregation. Alternatively, EDRF could exert its major influence on platelet reactivity at its site of release; that is at the EC surface, where it could modulate platelet function by stimulating platelet guanylate cyclase (17) [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] min. At the end of the incubation period prostacyclin (300 ng/ml) was added to the platelet-rich plasma (23) , and the mixture was transferred to plastic centrifuge tubes and centrifuged at 800 x g for 16 min. The supernatant was removed, and the platelet pellet was immediately resuspended in 10 ml of KRB and brought to 50 ml with the same buffer, and prostacyclin (300 ng/ml) was added before centrifuging at 800 x g for 16 min. The supernatant was aspirated, and the platelet pellet was resuspended in prostacyclin-free KRB and stored at 360C in a water bath until required. High-speed centrifugation of the final platelet suspension demonstrated that >95% of the radioactivity was associated with the blood platelets.
EC Cultures. ECs were isolated from bovine aorta by gently scraping the cells from the luminal surface and digesting the scrapings with 0.02% collagenase for 20 min. The collagenase reaction was stopped by adding 2 ml of Dulbecco's modified Eagle's medium containing 4 mM Lglutamine, 20% (vol/vol) fetal calf serum, penicillin at 100 units/ml, and streptomycin at 100,ug/ml, and the cells were centrifuged at 80 x g for 5 min. The cells were resuspended, divided between two T25 flasks, and grown to confluence. Cells were subpassaged once by removing from the T25 flasks with 0.2% trypsin/1 mM EDTA and culturing in 12-or 24-well culture plates. Monolayers were allowed to grow to confluence before being used in the platelet-adhesion studies.
Intact Bovine Aorta. Fresh bovine aortas were brought to the laboratory and trimmed free of fat and connective tissue, and the lumen was extensively washed with warm isotonic phosphate-buffered saline. The thinner-walled abdominal section was removed, placed in a beaker of KRB, and stored at 40C until its use 2-4 hr later in the platelet-adhesion studies.
Platelet Adhesion to Cultured ECs. Culture medium was aspirated from confluent monolayers of ECs in 12-or 24 -well culture plates, replaced by 1 ml of gassed KRB, and agitated in a shaking water bath for 10 min at 36TC. The medium was aspirated and replaced with 0.5 ml of platelet suspension. The drugs under investigation were added (in a final volume not exceeding 50 ,l) with human thrombin at 0.3 unit/ml, and the incubation was continued for 15 min. The platelet suspension was aspirated, and the monolayers were gently washed three times with 1 ml of KRB at 36°C. After the last wash 0.5 ml of hot (80°C) 1% Triton X-100 was added to the wells to extract the retained radioactivity, and 0.2-ml aliquots were taken to measure radioactivity by scintillation counting.
Platelet Adhesion to Intact Aorta. Platelet binding to intact aorta was measured in incubation chambers consisting of two Perspex plates (made in our workshop) (the upper plate had been drilled with six holes 1.5 cm in diameter) clamped together by six screws. When the aortic segments were placed between the two plates, tightening the screws made a water-tight seal with the upper plate forming six incubation chambers in which the chamber base was the aortic endothelial surface. When required, aortic segments were removed from ice-cold KRB, opened longitudinally between the intercostal vessels, quickly trimmed to fit the bottom Perspex plate, and placed in a beaker of oxygenated KRB at 36TC. After 15 min, the segments were removed and clamped between the two plates, and the incubation wells were filled with 2 ml of KRB and gently shaken for 5 min on the shaking platform of a water bath at 36TC. After removal of the incubation medium, 0.5 ml of platelet suspension was added to each well, and the platelet binding assay carried out as described for cultured ECs.
Uptake of [31H]Adenine by ECs. Representative samples of intact bovine aorta or cultured ECs were preincubated with KRB as described above. The medium was aspirated and replaced with 1 ml of KRB containing 350,000 dpm of [3H] adenine, and the cells were incubated for 20 min. At the end of the incubation, 0.2 ml of labeling solution was removed to measure radioactivity by scintillation counting, and the remainder was aspirated. The EC surface was washed three times with 1 ml of KRB and extracted with hot (80'C) 1% Triton X-100, and the residual radioactivity was determined.
Control Incubations. To determine the dependence of the experimental results on ECs, each set of experimental conditions was repeated either on gelatin-coated plastic tissue culture plates without ECs or fresh bovine aorta, the EC from which had been removed by scraping with a scalpel blade prior to the preincubation.
Platelet Aggregation. Platelet aggregation was measured in a Payton dual-channel aggregometer. Test agents were added 2 min before (or, for nitric oxide, simultaneously with) human thrombin (0.3 unit/ml).
Morphological Studies. Representative ECs from each type of experiment were examined for gross damage by inverted phase-contrast light microscopy at a magnification of x 40.
Expression of Results. Control binding represents the maximum binding observed with thrombin-stimulated platelets in the absence of any treatments other than indomethacin and is expressed as 100%. Platelet adhesion is expressed as a % of the appropriate controls.
RESULTS

Incorporation of [3H]Adenine by Platelets in Citrated
Plasma. Human platelets incubated in citrated plasma rapidly incorporated [3H]adenine and reached a plateau of -70% of total added radioactivity in 30-40 min (n = 2).
When the platelets were separated from the plasma, >95% of the radioactivity was intracellular. No significant increase in extracellular radioactivity was observed during storage of the platelet suspension at room temperature for periods of up to 4 hr. Morphological Changes. Incubation of confluent EC monolayers with unstimulated or thrombin-stimulated platelets produced no marked morphological changes in the appearance of the monolayers as determined by inverted phasecontrast light microscopy. At this level of resolution it would be possible to visualize areas of detachment and loss of the normal "cobblestone" appearance of the confluent monolayers.
Characterization of Platelet Adhesion to ECs. The dose of thrombin (0.3 unit/ml) used in these experiments produced a rapid, maximal, and irreversible aggregation of the washed indomethacin-treated platelets in an aggregometer. This concentration of thrombin also produced visible aggregates when added to suspensions of washed platelets incubated in gelatin-coated wells without ECs. However, when thrombin
, no platelet aggregates were observed although thrombin induced a significant increase in platelet adhesion to ECs. Thus, the model measures the adhesion of single activated platelets or small aggregates rather than the adhesion of the large aggregates routinely produced during maximum aggregation in the aggregometer cuvette.
When unstimulated [3H]adenine-labeled platelets were incubated for 30 min with cultured ECs or intact aortas, <3% (2.8 ± 0.7%; n = 9) of the added radioactivity remained adherent to the endothelial layer following the standard washing procedure. Similar results were seen in the absence of ECs. With thrombin-stimulated platelets a binding of 20 ± 2% (n = 6) of the added radioactivity was reached within 15 min and remained constant for at least a further 20-min incubation. However, without ECs the binding to the gelatin-coated well was =60%. The difference between stimulated and nonstimulated platelets was consistent over many experiments even though individual blood donors, bovine aortas, and the time taken for individual cell preparations to reach confluence differed between experiments. Both unstimulated and stimulated platelets adhered avidly (76%; n = 3) to aorta after removal of ECs by scraping.
For comparative purposes, the adhesion of platelets in individual experiments in control aorta or ECs was expressed as 100%. Bradykinin (400 ng/ml) produced a small reduction in the adhesion of thrombin-stimulated platelets to both cultured ECs and intact aortas (Fig. 1) . Although not significantly different from the controls, this reduction was consistent over many experiments.
Superoxide dismutase (SOD; 66 units/ml) significantly reduced platelet adhesion to intact bovine aorta to 70 ± 8% of controls (n = 10; P < 0.001). Addition of bradykinin as well as SOD further reduced adhesion to 48 ± 6% (n = 12; P < 0.05 compared to SOD alone). SOD reduced the adhesion of thrombin-stimulated platelets to confluent monolayers of ECs to =50% (Fig. 1) . With both SOD and bradykinin, there was a further (nonsignificant) decrease in platelet adhesion to 42 + 4% (n = 12; P < 0.1 compared to SOD alone). The antiadhesive action of bradykinin and SOD depended on the presence of ECs, for SOD with or without bradykinin did not influence either thrombin-induced platelet aggregation or promote disaggregation when added to platelet suspensions maximally aggregated with thrombin (0.3 unit/ml). SOD also reduced the adhesion of thrombin-stimulated platelets to gelatin-coated wells without ECs, but this effect was not increased by bradykinin. SOD did not decrease platelet binding to aorta when the EC had been removed by scraping.
With intact aorta, hemoglobin (10 j.M), which inactivates EDRF (25) , increased the adhesion of thrombin-stimulated platelets from 100% to 122 + 12% (n = 9; P < Q.05) in control and experimental samples treated with SOD plus or minus bradykinin. In cultured ECs, hemoglobin almost doubled (190 ± 42%; n = 6) platelet adhesion in control and experimental samples treated with SOD plus or minus bradykinin. In control experiments, hemoglobin (10 ILM) did not influence thrombin-induced platelet aggregation or disaggregation or increase the adhesion of thrombin-stimulated platelets to nonendothelial surfaces.
Inhibition of platelet aggregation by EDRF occurs through stimulation of guanylate cyclase that increases the concentration of cGMP (17) . The actions of cGMP are terminated by phosphodiesterases, and, as the selective cGMP phosphodiesterase inhibitor M&B 22,948 induces endotheliumdependent relaxation of blood vessels (26) , it might be expected that M&B 22,948 would influence the action of EDRF on platelet adhesion. In cultured ECs, M&B 22,948 (1 ,uM) produced a small, but insignificant, decrease in platelet adhesion but significantly increased the inhibitory effect of SOD or SOD plus bradykinin (Fig. 1) . These effects were absent when the ECs were treated with hemoglobin. At 10 ,uM, M&B 22,948 alone inhibited adhesion of thrombinstimulated platelets to intact aorta and cultured bovine ECs by =70%. This inhibitory effect was further increased by the addition of SOD and bradykinin (Fig. 1) . The inhibition of platelet adhesion induced by 10 ,uM M&B 22,948 was unexpected, as the concentration chosen had only a slight inhibitory effect on thrombin-induced platelet aggregation. This suggests that the effect of M&B 22,948 may depend on ECs. However, the effect of 10 ,uM M&B 22,948 was not prevented by hemoglobin (10 ,uM) , although hemoglobin reversed the small potentiation of M&B 22,948 activity produced by SOD. In addition, M&B 22,948 inhibited the adhesion of thrombin-stimulated platelets to plastic, suggesting that its major effect was to influence the reactivity of blood platelets regardless of the presence of ECs.
It has been suggested (27, 28) that EDRF is nitric oxide, and Palmer et al. (22) showed that the activity of EDRF could be accounted for by nitric oxide release from ECs. The effect of nitric oxide on platelet adhesion is shown in Fig. 2 . In two experiments on intact aorta, nitric oxide (at 11 and 40 nM) produced a dose-dependent inhibition of platelet adhesion that was potentiated by SOD. In experiments on cultured ECs, the addition of nitric oxide had variable effects on platelet adhesion. In six out of eight experiments nitric oxide reduced adhesion, but the degree of inhibition ranged from 10% to 80%. To prolong the half-life of the nitric acid, SOD was added to the washed platelet suspension immediately before nitric oxide, and, although the inhibitory effect of SOD was increased by nitric oxide, the inhibition was not significantly different from that seen with SOD alone.
DISCUSSION
Adherence of blood platelets to the vessel wall is an early event in the formation of intravascular thrombi and perhaps in the development of atherosclerosis (29 (1) (2) (3) (4) . ECs also produce EDRF, a vasodilator that is released in response to a variety of agonists, including biogenic amines, adenine nucleotides, and bradykinin (15) . In addition, EDRF is a potent inhibitor of platelet aggregation (16) (17) (18) , and this effect and the relaxation of smooth muscle are mediated by increases in intracellular levels of cGMP (12, 26, 30) .
Our experiments demonstrate that indomethacin-treated bovine ECs produce a factor that reduces the adhesion of thrombin-stimulated platelets and that shares many of the pharmacological properties of EDRF. Stimulation of cultured ECs with bradykinin results in a rapid transient release of EDRF (20) , which may be reflected in the small but consistent decrease in platelet adhesion seen after incubation with bradykinin. EDRF is rapidly inactivated by 07, and removal of this radical with SOD significantly prolongs the half-life of EDRF (31, 32) . Superoxide anions are produced by ECs (33) and platelet suspensions (34) ; furthermore, 07 increases platelet adhesion (35) . In our experiments, SOD caused significant inhibition of platelet adhesion to either intact aorta or cultured ECs. The antiadhesive action of SOD was increased by bradykinin and M&B 22,948. These effects of SOD were dependent upon the presence of intact ECs, for SOD did not influence thrombininduced platelet aggregation, and the SOD-induced reduction in the binding of thrombin-stimulated platelets to gelatin-coated wells or de-endothelialized strips of bovine aorta was not influenced by bradykinin.
EDRF is also inactivated by hemoglobin (25) , and our experiments demonstrate that hemoglobin not only reverses SOD-induced decreases in platelet adhesion but also significantly increases the adhesion of thrombin-stimulated platelets to intact aorta and cultured ECs. Like the effects of SOD, hemoglobin only influenced platelet function in the presence of intact endothelium. Hemoglobin did not increase the adhesion of thrombin-stimulated platelets to nonendothelial surfaces or influence thrombin-induced platelet aggregation. These opposing actions of SOD and hemoglobin suggest that there is a basal release of both 0°and EDRF from ECs and, furthermore, suggest that confluent monolayers release more EDRF and 07 than intact aorta, as removal of the 0°by SOD, or EDRF by hemoglobin, has a significantly greater effect on platelet adhesion to cultured cells than to intact aorta. In our experiments, the platelets were stimulated by thrombin, which produces endotheliumdependent relaxations of arterial smooth muscle (36) , suggesting that thrombin-stimulated platelets may release sufficient EDRF from ECs to account for the opposing effects of SOD and hemoglobin. However, thrombin did not stimulate EDRF release from the same line of ECs cultured on microcarrier beads (37) , and the concept of basal release of EDRF is supported by in vivo (38, 39) and in vitro experiments. For example, in resting unstimulated isolated arteries, the basal cGMP levels are higher in endothelium-intact arteries compared to denuded arteries (30, (40) (41) (42) , an effect attributed to EDRF-induced stimulation of soluble guanylate cyclase (40, 43) . Furthermore, removal of 07 with SOD results in endothelium-dependent relaxation of strips of rabbit aorta (44) , and superfusion of ECs grown on microcarriers with SOD also reveals a basal release of EDRF as detected by endothelium-denuded blood vessels (31, 37) .
Our results suggest that in addition to locally induced vasodilatation and the antiaggregatory action of EDRF, the production of EDRF by ECs prevents adhesion of activated platelets and perhaps other blood cells to the endothelium. The simultaneous release of both prostaglandin I2 and EDRF could provide a powerful feed-back mechanism representing an adaptive response that in normal blood vessels would inhibit further aggregation/adhesion and by promoting vasodilatation assist in the removal of microthrombi from the vascular bed. The hypothesis of an adaptive mechanism is further strengthened by the marked synergy that exists in inhibiting platelet aggregation between prostacyclin and nitro-vasodilators [such as nitroprusside (45) ], prostacyclin, and EDRF (46) , and the observation that the receptormediated release of prostacyclin and EDRF is coupled (37) . Whether such an adaptive mechanism is lost in diseased blood vessels remains to be established. However, the production of EDRF is attenuated in atherosclerosis (47) and hypertension (48) , whereas prostacyclin production is reported to be either increased (49) or decreased (50) in atherosclerosis. This suggests that alteration in endothelial production of basal mediators (prostaglandin 12 and EDRF) may contribute to the pathological mechanisms in cardiovascular disease.
Note: While this paper was in preparation, similar observations on the role of EDRF on platelet adhesion were published by Radomski et al. (51) .
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